Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Cholangiocarcinoma 2Sarcoma 1Recurrence 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Oxaliplatin 67Capecitabine 60Fluorouracil 58Bevacizumab 54Gemcitabine 51Paclitaxel 50Leucovorin 50Irinotecan 40Docetaxel 39Carboplatin 39Cisplatin 38pembrolizumab 37Nivolumab 37Cetuximab 35Sunitinib 25Trastuzumab 24Radiosurgery 24Radiotherapy 21Doxorubicin 21Cyclophosphamide 21Panitumumab 20Drug Therapy 19Pemetrexed 18Everolimus 18Sorafenib 17Interleukin-2 16Fulvestrant 16Albumin-Bound Paclitaxel 16atezolizumab 15Erlotinib Hydrochloride 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Metastasis × Yttrium-90 × Clear all
NCT01898962 2013-07-15

Definitive Therapy for Oligometastatic Solid Malignancies

Rocky Mountain Cancer Centers

Phase 2 Unknown
110 enrolled
Sarcoma

Neoplasm Metastasis, Recurrence, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡